Search - tctmd.com

Displaying 941 - 960 of 1075

Sort: Relevancy | Date

Presentation TCT 2016

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

Presenter: Raj Makkar, Lars Sondergaard, John G. Webb

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Presenter: Raj Makkar, Lars Sondergaard, Helene Eltchaninoff

October 31, 2016

Presentation TCT 2016

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Presenter: Raj Makkar, Lars Sondergaard, A. Pieter Kappetein

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Presenter: Raj Makkar, Lars Sondergaard, Haim Danenberg

October 31, 2016

Presentation TCT 2016

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Presenter: Raj Makkar, Lars Sondergaard, Axel Linke

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

TCT 78: Incidence and Outcomes of Vascular Complications and Bleeding Events in Patients Undergoing TAVR in Contemporary U.S. Practice: Insights From the STS/ACC TVT Registry®

Presenter: John M. Lasala, Philippe Pibarot, Matthew Sherwood

October 31, 2016

Presentation TCT 2016

Complications After MitraClip: Frequency, Avoidance, and Treatment

Presenter: Alec S. Vahanian, Ralph Stephan von Bardeleben, Scott Lim

October 30, 2016

Presentation TCT 2016

Brazil Presents a Case: Complex Access in TAVI the Transcaval Approach

Presenter: Rui Campante Teles, Marcelo Jose de Carvalho Cantarelli, Dimytri Alexandre Siqueira

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Complications of Transseptal Puncture: Recognition and Management

Presenter: Samir R. Kapadia, Horst Sievert

October 30, 2016

Presentation TCT 2016

A Case Series of MitraClip Complications

Presenter: Anita Asgar, Scott Lim, Stephan Baldus

October 30, 2016

News Conference News TCT 2016

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

Yael L. Maxwell

October 29, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Conference News PCR London Valves 2016

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

Advertisement

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Flash Debate: Counterpoint Cerebral Protection Is an Unnecessary and Costly Accessory!

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

TCT 78: Incidence and Outcomes of Vascular Complications and Bleeding Events in Patients Undergoing TAVR in Contemporary U.S. Practice: Insights From the STS/ACC TVT Registry®

Complications After MitraClip: Frequency, Avoidance, and Treatment

Brazil Presents a Case: Complex Access in TAVI the Transcaval Approach

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Complications of Transseptal Puncture: Recognition and Management

A Case Series of MitraClip Complications

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content